華潤醫藥集團有限公司
China Resources Pharmaceutical Group Limited

(Incorporated in Hong Kong with limited liability)

(Stock Code: 3320)

ANNOUNCEMENT

RESULTS ESTIMATE OF CR BOYA BIO-PHARMACEUTICAL FOR THE YEAR ENDED 31 DECEMBER 2025

On 30 January 2026, CR Boya Bio-pharmaceutical released its results estimate for the year ended 31 December 2025.

China Resources Boya Bio-pharmaceutical Group Company Limited (華潤博雅生物製藥集團股份有限公司) ("**CR Boya Bio-pharmaceutical**") is a company incorporated in the People's Republic of China. The shares of CR Boya Bio-pharmaceutical are listed on the Shenzhen Stock Exchange. As of the date of this announcement, China Resources Pharmaceutical Group Limited (the "**Company**", together with its subsidiaries, the "**Group**") indirectly holds approximately 30.48% of the total share capital and approximately 41.79% voting rights in the total share capital of CR Boya Bio-pharmaceutical, and therefore, CR Boya Bio-pharmaceutical is a subsidiary of the Company.

On 30 January 2026, CR Boya Bio-pharmaceutical released its results estimate for the year ended 31 December 2025, in which, it announced that the net profit attributable to the shareholders of CR Boya Bio-pharmaceutical for the year ended 31 December 2025 is estimated to range from approximately RMB105.00 million to RMB136.50 million (as compared to the same period last year of net profit of approximately RMB396.99 million), net loss attributable to the shareholders of CR Boya Bio-pharmaceutical excluding non-recurring gain or loss is estimated to range from approximately RMB7.50 million to RMB15.00 million (as compared to the same period last year of net profit of approximately RMB301.57 million) (the "**CR Boya Bio-pharmaceutical Results Estimate**").

During the reporting period, CR Boya Bio-pharmaceutical firmly implemented the China Resources "1246" model, and leveraging on the "four reshaping" (value reshaping, business reshaping, organizational reshaping, and mentality reshaping), it overcame difficulties in a complex and volatile market, led in academics, digested historical risks, and is expected to achieve a year-on-year increase of 10.00% to 25.00% in operating revenue, mainly due to the acquisition of Green Cross HK Holdings Limited.

The significant decrease in the net profit attributable to the shareholders of CR Boya Bio-pharmaceutical for the year ended 31 December 2025 was mainly attributable to the downturn in the hyaluronic acid market in 2025, the market for a medical aesthetic product distributed by Anhui Gelinke Pharmaceutical Sales Co., Ltd. (安徽格林克醫藥銷售有限公司) (a wholly-owned subsidiary of Green Cross HK Holdings Limited, which has been acquired by CR Boya Bio-pharmaceutical in November 2024), resulting in an aggregate impairment of intangible assets (franchise rights) and impairment of goodwill of approximately RMB300 million. In addition, the net profit of CR Boya Bio-pharmaceutical was impacted (reduced) by approximately RMB80 million due to assessed appreciation inventory resale and asset depreciation and amortization from the acquisition of Green Cross HK Holdings Limited. Further, CR Boya Bio-pharmaceutical's blood products business was affected by factors such as centralized procurement expansion, DRG/DIP reform, medical insurance fee control, and focused monitoring of rational drug use, resulting in a decrease in clinical prescriptions and decline in demand, while at the same time, market competition continued to intensify, which led to a year-on-year decline in the gross profit margin of CR Boya Bio-pharmaceutical's blood products business during the reporting period.

During the reporting period, CR Boya Bio-pharmaceutical expects the impact of non-recurring gains and losses on net profit to be approximately RMB120 million, mainly due to factors such as government subsidies, asset disposal and wealth management income. For the year ended 31 December 2024, the non-recurring gains and losses was RMB95 million.

The CR Boya Bio-pharmaceutical Results Estimate was prepared in accordance with the PRC Generally Accepted Accounting Principles and has not been audited or reviewed. For details of the financial data, those to be disclosed in the annual report for the year ended 31 December 2025 to be issued by CR Boya Bio-pharmaceutical shall prevail.

The financial information in this announcement is limited to CR Boya Bio-pharmaceutical only and does not represent or provide a complete view of the operational or financial status of the Group.

Shareholders of the Company and potential investors are advised to exercise caution when dealing in the shares of the Company.

By Order of the Board
China Resources Pharmaceutical Group Limited
Mr. Bai Xiaosong
Chairman

PRC, 30 January 2026

As at the date of this announcement, the Board comprises Mr. Bai Xiaosong as chairman and executive Director, Mr. Cheng Jie and Mr. Liu Changan as executive Directors, Mdm. Guo Wei, Mr. Sun Yongqiang, Mr. Wang Yuhang, Mr. Guo Chuan and Mdm. Jiao Ruifang as non-executive Directors and Mdm. Chiu Mun Wai, Mr. Fu Tingmei, Mr. Zhang Kejian and Mr. Shi Luwen as independent non-executive Directors.